Crenolanib, a tyrosine kinase inhibitor developed as a selective and potent PDGFRα/β inhibitor, has also high affinity for FLT3, including both FLT3-ITD and FLT3-TKD mutations (24), and a phase 1 pilot study is currently assessing its toxicity profile in combination with Sorafenib in relapsed or refractory pediatric AML with mutated FLT3 (NCT02270788). This evidence concerns the gene FLT3 and acute myeloid leukemia.